Mitomics Announces U.S. Sales and Marketing Agreement with LabMD

THUNDER BAY, Ontario--(BUSINESS WIRE)--Mitomics, a world leader in the research and development of mitochondrial genome-based products, today announced a non-exclusive agreement with LabMD, Inc., an Atlanta-based clinical pathology laboratory, to market Mitomics’ flagship product, the Prostate Core Mitomic Test™ (PCMT), in the United States.

MORE ON THIS TOPIC